Cite
Bortezomib salvage followed by a Phase I/ II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
MLA
Nishihori, Taiga, et al. “Bortezomib Salvage Followed by a Phase I/ II Study of Bortezomib plus High-Dose Melphalan and Tandem Autologous Transplantation for Patients with Primary Resistant Myeloma.” British Journal of Haematology, vol. 157, no. 5, June 2012, pp. 553–63. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2012.09099.x.
APA
Nishihori, T., Alekshun, T. J., Shain, K., Sullivan, D. M., Baz, R., Perez, L., Pidala, J., Kharfan-Dabaja, M. A., Ochoa-Bayona, J. L., Fernandez, H. F., Yarde, D. N., Oliveira, V., Fulp, W., Han, G., Kim, J., Chen, D.-T., Raychaudhuri, J., Dalton, W., Anasetti, C., & Alsina, M. (2012). Bortezomib salvage followed by a Phase I/ II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology, 157(5), 553–563. https://doi.org/10.1111/j.1365-2141.2012.09099.x
Chicago
Nishihori, Taiga, Todd J. Alekshun, Kenneth Shain, Daniel M. Sullivan, Rachid Baz, Lia Perez, Joseph Pidala, et al. 2012. “Bortezomib Salvage Followed by a Phase I/ II Study of Bortezomib plus High-Dose Melphalan and Tandem Autologous Transplantation for Patients with Primary Resistant Myeloma.” British Journal of Haematology 157 (5): 553–63. doi:10.1111/j.1365-2141.2012.09099.x.